House of Commons committee looks at barriers to R&D and entrepreneurship in tackling cancer
Rebates paid on the sale of drugs to the NHS have left cancer research in an “unsustainable position”, MPs attending a committee on the future of cancer have heard.
The voluntary scheme for branded medicines pricing (Vpas) caps the rate of NHS spending on medicines to keep its bill affordable. If it goes beyond the cap, drug companies pay rebates on their sales back to the NHS.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.